Reports Q revenue $1.658M vs $983,000 last year. “XOMA is increasingly being recognized for enabling innovative biotech companies to unlock value in the face of a challenging financing environment. To date, the team has added three new assets to XOMA’s royalty and milestone portfolio to complement the growing cash flows generated by VABYSMO,” stated Owen Hughes, Executive Chairman of XOMA. “And over the ensuing quarters, the potential approval of arimoclomol, a first-in-class molecule for Niemann-Pick Disease Type C and tovorafenib for relapsed or progressive pediatric low-grade glioma, as well as the expansion of IXINITY’s label into the pediatric population with Hemophilia B, should address critical unmet needs for patients and drive increasing cash flows for XOMA shareholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on XOMA:
- XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
- XOMA Earnings this Week: How Will it Perform?
- XOMA Added to the Russell 2000® and Russell 3000® Indexes
- Xoma added to Russell 2000, Russell 3000 Indexes
- XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset